Singapore markets closed
Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,116.17 +16.21 (+0.32%) Dow
38,386.09 +146.43 (+0.38%) Nasdaq
15,983.08 +55.18 (+0.35%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,262.12 -76.94 (-5.75%)
PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed price. Currency in IDR
Add to watchlist
At close: 04:11PM WIB
| Previous close | 1,405.00 |
| Open | 1,410.00 |
| Bid | 1,755.00 x 0 |
| Ask | 1,055.00 x 0 |
| Day's range | 1,405.00 - 1,495.00 |
| 52-week range | 1,375.00 - 2,200.00 |
| Volume | |
| Avg. volume | 36,815,213 |
| Market cap | 67.302T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 24.31 |
| EPS (TTM) | 59.85 |
| Earnings date | 29 Apr 2024 - 30 Apr 2024 |
| Forward dividend & yield | 38.00 (2.70%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | 1,752.50 |
Business WireGenexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.